PTJ
ASND icon

Paul Tudor Jones’s Ascendis Pharma A/S ASND Stock Holding History

Paul Tudor Jones’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213K Sell
800
-33,300
-98% -$7.78M ﹤0.01% 3295
2026
Q1 		$7.8M Buy
+34,100
New +$7.64M 0.01% 889

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Paul Tudor Jones's ASND Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 16,625 shares worth $4.43M. The stake represents 0.01% of the portfolio and ranks #1366 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in ASND as recently as Q1 2025.

Paul Tudor Jones first reported a position in ASND in Q3 2017 and has held it in 16 quarters since. The position peaked at $4.55M in Q2 2024. 310 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Paul Tudor Jones held 16,625 shares of Ascendis Pharma A/S worth $4.43M as of Q2 2026.
  • Ascendis Pharma A/S was a new Paul Tudor Jones position in Q2 2026.
  • Ascendis Pharma A/S made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1366 holding.
  • Paul Tudor Jones first reported a position in Ascendis Pharma A/S in Q3 2017 and has held it in 16 quarters since.
  • Paul Tudor Jones's Ascendis Pharma A/S position peaked at $4.55M in Q2 2024.
  • 310 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.